Development of CG620953 (TYK2/JAK1 degrader) for autoimmune diseases
A novel drug discovery program for CG620953, a dual TYK2/JAK1 degrader, being developed preclinically for autoimmune diseases with the aim of filing IND applications in the United States and China.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.